구조모아 (StructureMoa)항암 chemical structure spider web
방문JohnsonJohnsonJanssen
분석
큐레이션 브리핑
경쟁 포지션: FcRn class next to Vyvgart; split on cycle vs continuous dosing and on MuSK / wAIHA vs CIDP.
기전. Occupies FcRn and blocks IgG recycling, lowering total and pathogenic IgG. Autoantibody titers fall while dosing continues and recover when it stops.
우선 정리한 핵심 프로그램입니다. 공개 출처가 있는 필드만 표시합니다.
구조화 데이터
FcRn
Generalized myasthenia gravis (AChR or MuSK antibody-positive, age ≥12); warm autoimmune hemolytic anemia
US
Approved
imaavy · nipocalimab · Imaavy · M281 · nipocalimab-aahu
2026-09-10
Data Confidence · High
Development Signal · Established
Human IgG1 monoclonal antibody (FcRn antagonist)
High-affinity blockade of FcRn that lowers circulating IgG, including pathogenic autoantibodies
Continuous q2w maintenance after loading, MuSK coverage, and a wAIHA indication — not a CIDP or subcutaneous Hytrulo story.
구조화 데이터
Continuous q2w maintenance after loading, MuSK coverage, and a wAIHA indication — not a CIDP or subcutaneous Hytrulo story.
Non-IgG-mediated disease and incomplete FcRn occupancy.
Human IgG1 monoclonal antibody (FcRn antagonist)
FcRn · MG-ADL, QMG, AChR/MuSK serology; hemoglobin in wAIHA.
Infection monitoring while total IgG is lowered; hypersensitivity
FcRn class next to Vyvgart; split on cycle vs continuous dosing and on MuSK / wAIHA vs CIDP.
gMG with AChR or MuSK antibodies (age ≥12); wAIHA after corticosteroids
After or with steroids / conventional immunosuppressants per label
IV
Loading then every two weeks
Infection monitoring while total IgG is lowered; hypersensitivity
FcRn class next to Vyvgart; split on cycle vs continuous dosing and on MuSK / wAIHA vs CIDP.
Occupies FcRn and blocks IgG recycling, lowering total and pathogenic IgG. Autoantibody titers fall while dosing continues and recover when it stops.
N/A — the mechanism is IgG catabolism, not lymphocyte depletion.
MG-ADL, QMG, AChR/MuSK serology; hemoglobin in wAIHA.
Non-IgG-mediated disease and incomplete FcRn occupancy.
구조화 데이터
Human
Supports q2w maintenance after loading
Total IgG reduction, MG-ADL, hemoglobin
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
구조화 데이터
ClinicalTrials.gov에 등록된 완료 예정일입니다. 추정이며 결과 발표를 단정하지 않습니다.
FDA approval (gMG, AChR or MuSK, age ≥12)
APPROVAL · 2025년 4월
FDA approval (warm autoimmune hemolytic anemia)
APPROVAL · 2026년 8월
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.
JohnsonJohnsonJanssen
분석
큐레이션 브리핑
경쟁 포지션: FcRn class next to Vyvgart; split on cycle vs continuous dosing and on MuSK / wAIHA vs CIDP.
기전. Occupies FcRn and blocks IgG recycling, lowering total and pathogenic IgG. Autoantibody titers fall while dosing continues and recover when it stops.
우선 정리한 핵심 프로그램입니다. 공개 출처가 있는 필드만 표시합니다.
구조화 데이터
FcRn
Generalized myasthenia gravis (AChR or MuSK antibody-positive, age ≥12); warm autoimmune hemolytic anemia
US
Approved
imaavy · nipocalimab · Imaavy · M281 · nipocalimab-aahu
2026-09-10
Data Confidence · High
Development Signal · Established
Human IgG1 monoclonal antibody (FcRn antagonist)
High-affinity blockade of FcRn that lowers circulating IgG, including pathogenic autoantibodies
Continuous q2w maintenance after loading, MuSK coverage, and a wAIHA indication — not a CIDP or subcutaneous Hytrulo story.
구조화 데이터
Continuous q2w maintenance after loading, MuSK coverage, and a wAIHA indication — not a CIDP or subcutaneous Hytrulo story.
Non-IgG-mediated disease and incomplete FcRn occupancy.
Human IgG1 monoclonal antibody (FcRn antagonist)
FcRn · MG-ADL, QMG, AChR/MuSK serology; hemoglobin in wAIHA.
Infection monitoring while total IgG is lowered; hypersensitivity
FcRn class next to Vyvgart; split on cycle vs continuous dosing and on MuSK / wAIHA vs CIDP.
gMG with AChR or MuSK antibodies (age ≥12); wAIHA after corticosteroids
After or with steroids / conventional immunosuppressants per label
IV
Loading then every two weeks
Infection monitoring while total IgG is lowered; hypersensitivity
FcRn class next to Vyvgart; split on cycle vs continuous dosing and on MuSK / wAIHA vs CIDP.
Occupies FcRn and blocks IgG recycling, lowering total and pathogenic IgG. Autoantibody titers fall while dosing continues and recover when it stops.
N/A — the mechanism is IgG catabolism, not lymphocyte depletion.
MG-ADL, QMG, AChR/MuSK serology; hemoglobin in wAIHA.
Non-IgG-mediated disease and incomplete FcRn occupancy.
구조화 데이터
Human
Supports q2w maintenance after loading
Total IgG reduction, MG-ADL, hemoglobin
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
구조화 데이터
ClinicalTrials.gov에 등록된 완료 예정일입니다. 추정이며 결과 발표를 단정하지 않습니다.
FDA approval (gMG, AChR or MuSK, age ≥12)
APPROVAL · 2025년 4월
FDA approval (warm autoimmune hemolytic anemia)
APPROVAL · 2026년 8월
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.